Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2008 Jan;7(1):68-83.

Neurophysiological biomarkers for drug development in schizophrenia.

Author information

1
Nathan Kline Institute for Schizophrenia Research/New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, New York 10962, USA.

Abstract

Schizophrenia represents a pervasive deficit in brain function, leading to hallucinations and delusions, social withdrawal and a decline in cognitive performance. As the underlying genetic and neuronal abnormalities in schizophrenia are largely unknown, it is challenging to measure the severity of its symptoms objectively, or to design and evaluate psychotherapeutic interventions. Recent advances in neurophysiological techniques provide new opportunities to measure abnormal brain functions in patients with schizophrenia and to compare these with drug-induced alterations. Moreover, many of these neurophysiological processes are phylogenetically conserved and can be modelled in preclinical studies, offering unique opportunities for use as translational biomarkers in schizophrenia drug discovery.

PMID:
18064038
PMCID:
PMC2753449
DOI:
10.1038/nrd2463
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center